Xenon Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell XENE and other ETFs, options, and stocks.

About XENE

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. 

CEO
Ian C. Mortimer
CEOIan C. Mortimer
Employees
370
Employees370
Headquarters
Burnaby, British Columbia
HeadquartersBurnaby, British Columbia
Founded
1996
Founded1996
Employees
370
Employees370

XENE Key Statistics

Market cap
4.60B
Market cap4.60B
Price-Earnings ratio
-12.66
Price-Earnings ratio-12.66
Dividend yield
Dividend yield
Average volume
3.33M
Average volume3.33M
High today
$56.19
High today$56.19
Low today
$54.19
Low today$54.19
Open price
$54.41
Open price$54.41
Volume
993.56K
Volume993.56K
52 Week high
$63.95
52 Week high$63.95
52 Week low
$26.74
52 Week low$26.74

Stock Snapshot

Xenon Pharmaceuticals(XENE) stock is priced at $55.20, giving the company a market capitalization of 4.6B. It carries a P/E multiple of -12.66.

On 2026-03-18, Xenon Pharmaceuticals(XENE) stock moved within a range of $54.19 to $56.19. With shares now at $55.20, the stock is trading +1.9% above its intraday low and -1.8% below the session's peak.

Trading volume for Xenon Pharmaceuticals(XENE) stock has reached 993.56K, versus its average volume of 3.33M.

Over the past 52 weeks, Xenon Pharmaceuticals(XENE) stock has traded between a high of $63.95 and a low of $26.74.

Over the past 52 weeks, Xenon Pharmaceuticals(XENE) stock has traded between a high of $63.95 and a low of $26.74.

XENE News

Simply Wall St 8h
Assessing Xenon Pharmaceuticals Valuation After Positive Phase 3 X TOLE2 Azetukalner Results

Xenon Pharmaceuticals (XENE) has drawn fresh attention after reporting positive Phase 3 X TOLE2 results for azetukalner in focal onset seizures, followed closel...

Assessing Xenon Pharmaceuticals Valuation After Positive Phase 3 X TOLE2 Azetukalner Results
TipRanks 4d
Xenon Sets Date for 2026 Annual Shareholder Meeting

Xenon ( (XENE) ) has shared an update. Xenon Pharmaceuticals Inc. advised Canadian securities regulators on March 13, 2026 that it has set June 2, 2026 as the...

TipRanks 5d
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors

Xenon Pharmaceuticals (XENE) announced an update on their ongoing clinical study. Xenon Pharmaceuticals Inc. (XENE) has completed its Phase 3 X-TOLE2 trial, of...

Analyst ratings

100%

of 20 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own XENE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.